Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention

Paediatr Drugs. 2024 May;26(3):259-275. doi: 10.1007/s40272-024-00626-w. Epub 2024 Apr 2.

Abstract

Necrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, maternal and environmental factors, and intestinal ischemia) and reports treatment modalities surrounding NEC, including pain medications and common antibiotic combinations, the rationale for these combinations, and recent antibiotic stewardship approaches surrounding NEC treatment. This review also highlights the effect of early antibiotic exposure, infections, proton pump inhibitors (PPIs), and H2 receptor antagonists on the microbiota and how these risk factors can increase the chances of NEC. Finally, modern prevention strategies including the use of human breast milk and standardized feeding regimens are discussed, as well as promising new preventative and treatment options for NEC including probiotics and stem cell therapy.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Enterocolitis, Necrotizing* / physiopathology
  • Enterocolitis, Necrotizing* / prevention & control
  • Enterocolitis, Necrotizing* / therapy
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Milk, Human*
  • Probiotics / therapeutic use
  • Risk Factors

Substances

  • Anti-Bacterial Agents